

Figure Captions

Figure S1 Network pharmacology Diagram of Cyanidin-3-*O*-glucoside.(A) Related targets of cyanidin-3-*O*-glucoside, the green circular and red polygons respectively represented cyanidin-3-*O*-glucoside -targeted genes and cyanidin-3-*O*-glucoside. (B) Venn map of cyanidin-3-*O*-glucoside target and ALD target.

Table S1. Shared target information of cyanidin-3-*O*-glucoside.

Figure S2. PPI network of the intersection target of cyanidin-3-*O*-glucoside for ALD.

Figure S3. Histogram of Go analysis of cyanidin-3-*O*-glucoside (A) The enriched terms in biological process (BP); (B) The enriched terms in cellular component (CC); (C) The enriched terms in molecular function (MF).

Figure S4 KEGG pathway diagram of cyanidin-3-*O*-glucoside.

Figure S5. “Component-target-pathway-disease” network diagram.





Figure S1. Network pharmacology Diagram of Cyanidin-3-*O*-glucoside.(A) Related targets of cyanidin-3-*O*-glucoside, the green circular and red polygons respectively represented cyanidin-3-*O*-glucoside -targeted genes and cyanidin-3-*O*-glucoside. (B) Venn map of cyanidin-3-*O*-glucoside target and ALD target.


Table S1. Shared target information of cyanidin-3-O-glucoside

| No | Target | Symbol | No | Target | Symbol |
|----|---|----------------|----|---|----------------|
| 1 | Lymphocyte differentiation antigen CD38 | CD38 | 42 | DNA topoisomerase II alpha | TOP2A |
| 2 | NADPH oxidase 4 | NOX4 | 43 | Monoamine oxidase A | MAOA |
| 3 | Aldose reductase | AKR1B1 | 44 | Insulin-like growth factor I receptor | IGF1R |
| 4 | Adrenergic receptor alpha-2 | ADRA2 C | 45 | Tyrosine-protein kinase receptor FLT3 | FLT3 |
| 5 | Carbonic anhydrase II | CA2 | 46 | Cytochrome P450 19A1 | CYP19A1 |
| 6 | Carbonic anhydrase IV | CA4 | 47 | Insulin receptor | INSR |
| 7 | Acetylcholinesterase | ACHE ADRA2 | 48 | Serine/threonine-protein kinase Aurora-B | AURKB |
| 8 | Alpha-2a adrenergic receptor | A RPS6KA | 49 | Dopamine D4 receptor Myosin light chain kinase, smooth | DRD4 |
| 9 | Ribosomal protein S6 kinase alpha 3 | 3 | 50 | muscle | MYLK |
| 10 | Cyclooxygenase-2 | PTGS2 | 51 | Myeloperoxidase | MPO |
| 11 | Xanthine dehydrogenase | XDH | 52 | PI3-kinase p85-alpha subunit | PIK3R1 |
| 12 | Phosphodiesterase 5A | PDE5A | 53 | Death-associated protein kinase 1 | DAPK1 |
| 13 | TNF-alpha | TNF | 54 | Liver glycogen phosphorylase | PYGL |
| 14 | Interleukin-2 | IL2 ADORA | 55 | Tyrosine-protein kinase SYK | SYK |
| 15 | Adenosine A1 receptor (by homology) | 1 | 56 | Glycogen synthase kinase-3 beta | GSK3B |
| 16 | Arachidonate 5-lipoxygenase | ALOX5 | 57 | Focal adhesion kinase 1 Vascular endothelial growth factor | PTK2 |
| 17 | Carbonic anhydrase I | CA1 | 58 | receptor 2 | KDR |
| 18 | Carbonic anhydrase IX | CA9 | 59 | Matrix metalloproteinase 13 | MMP13 |
| 19 | Aldehyde dehydrogenase | ALDH2 | 60 | Matrix metalloproteinase 3 | MMP3 |
| 20 | Telomerase reverse transcriptase | TERT | 61 | Carbonic anhydrase III | CA3 |
| 21 | Plasminogen | PLG | 62 | Arachidonate 15-lipoxygenase | ALOX15 |
| 22 | ATP-binding cassette sub-family G member 2 | ABCG2 ADORA | 63 | Serine/threonine-protein kinase PLK1 | PLK1 |
| 23 | Adenosine A3 receptor | 3 | 64 | Cyclin-dependent kinase 1 | CDK1 |
| 24 | Thrombin | F2 | 65 | Matrix metalloproteinase 9 | MMP9 |
| 25 | Glyoxalase I | GLO1 | 66 | PI3-kinase p110-gamma subunit | PIK3CG |
| 26 | LXR-alpha | NR1H3 | 67 | Matrix metalloproteinase 2 | MMP2 CSNK2A |
| 27 | Beta amyloid A4 protein | APP | 68 | Casein kinase II alpha | 1 |
| 28 | Tyrosine-protein kinase SRC | SRC | 69 | Arachidonate 12-lipoxygenase | ALOX12 |
| 29 | Cytochrome P450 1B1 | CYP1B1 | 70 | Hepatocyte growth factor receptor | MET |
| 30 | Sodium/glucose cotransporter 2 Induced myeloid leukemia cell | SLC5A2 | 71 | Interleukin-8 receptor A | CXCR1 |
| 31 | differentiation protein Mcl-1 | MCL1 | 72 | CaM kinase II beta | CAMK2B |
| 32 | Sodium/glucose cotransporter 1 | SLC5A1 | 73 | ALK tyrosine kinase receptor | ALK |


| | | | | | |
|----|---|-------------|----|--|---------|
| 33 | Hypoxia-inducible factor 1 alpha Multidrug resistance-associated protein | HIF1A | 74 | Serine/threonine-protein kinase AKT | AKT1 |
| 34 | 1 | ABCC1 | 75 | Phospholipase A2 group 1B | PLA2G1B |
| 35 | P-glycoprotein 1 (by homology) | ABCB1 | 76 | Beta-secretase 1 | BACE1 |
| 36 | Sigma opioid receptor | SIGMA R1 | 77 | Tyrosine-protein kinase receptor UFO DNA-(apurinic or apyrimidinic site) lyase | AXL |
| 37 | Dopamine D2 receptor (by homology) Epidermal growth factor receptor | DRD2 | 78 | Aldo-keto reductase family 1 member | APEX1 |
| 38 | erbB1 | EGFR | 79 | C2 (by homology) | AKR1C2 |
| 39 | Adenosine A2a receptor (by homology) | ADORA 2A | 80 | Aldo-keto reductase family 1 member C1 (by homology) | AKR1C1 |
| 40 | Microtubule-associated protein tau | MAPT | 81 | C4 (by homology) | AKR1C4 |
| 41 | Vasopressin V2 receptor | AVPR2 | 82 | Aldehyde reductase (by homology) | AKR1A1 |



A



B



C

Figure S3. Histogram of Go analysis of cyanidin-3-*O*-glucoside (A) The enriched terms in biological process (BP); (B) The enriched terms in cellular component (CC); (C) The enriched terms in molecular function (MF).




Figure S4 KEGG pathway diagram of cyanidin-3-*O*-glucoside.




Figure S5. “Component-target-pathway-disease” network diagram.